Skip to main content

Recombinant Mouse CREG Protein

R&D Systems, part of Bio-Techne | Catalog # 1697-CR

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
1697-CR-025/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
1697-CR-025

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived mouse CREG protein
Arg32-Gln220, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Arg32

Predicted Molecular Mass

22.3 kDa

SDS-PAGE

25-35 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.

When Recombinant Human IGF-II R (Catalog # 6418-GR) is immobilized at 2 μg/mL (100 μL/well), the concentration of Recombinant Mouse CREG that produces 50% of the optimal binding response is found to be approximately 3-15 ng/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 1697-CR
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 1697-CR/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CREG

Cellular repressor of E1A-stimulated genes (CREG) is a 28 ‑ 33 kDa member of the CREG family of proteins. Mouse CREG is synthesized as a 220 amino acid (aa) precursor that contains a 31 aa signal sequence and a 189 aa mature chain (SwissProt # O88668) (1, 2). Mass spectrometric analysis of recombinant CREG revealed that the protein contains phosphorylated oligosaccharides at either of its two N-glycosylation sites (1). Mouse CREG shares 78% aa sequence identity with human CREG. CREG is a secreted glycoprotein ubiquitously expressed in mammals (3). It is largely secreted by fibroblasts missing both mannose 6‑phosphate receptors (1). This is not observed in cells lacking only one of them (1). CREG is proposed to participate in a wide range of cellular processes. Among them, CREG has been found to antagonize transcriptional and cellular transformation by the adenoviral E1A oncoprotein (1, 3, 4), to induce differentiation while attenuating cellular proliferation (1, 3, 4, 5), to regulate the levels of the signaling kinases ERK1/2 (1, 6), and to mediate the glucocorticoid-induced proliferation of ileal epithelial cells (1, 7). These observations have led to the notion that CREG may play an important role in the control of cell growth and differentiation (1, 3). In a search for potential interaction partners, CREG was found to bind directly to the mannose 6‑phosphate/insulin-like growth factor II receptor (M6P/IGF2R) (1). Since this interaction was shown to depend on N-glycosylation of CREG, it was inferred that CREG binds to M6P/IGF2R via M6P residues located in its N-glycans (1, 3, 8). Other studies have shown that CREG interacts with M6P/IGF2R in an M6P-dependent manner (1, 9 ‑ 12). Recent results indicate that human CREG carries M6P moieties at two of its three N-glycosylation sites (1, 13). Han et al. showed that CREG is significantly up-regulated at both the mRNA and protein levels during phenotypic conversion of proliferative and synthetic smooth muscle cells (SMCs) to non-proliferative and differentiated SMCs in vitro (3). In addition, CREG over‑expression in cultured SMCs may inhibit cellular proliferation and promote differentiation; whereas CREG knockdown prevents serum starvation‑induced SMCs maturation and growth arrest (3). Moreover, CREG is down-regulated in the vascular media after balloon injury in the rabbit carotid artery (3). Adenovirus-mediated CREG over‑expression in injured arteries inhibits SMCs proliferation and attenuates neointimal hyperplasia in vivo (3, 14). Research thus suggests that CREG plays a critical role in keeping cell or tissue in a mature, homeostatic state by antagonizing pathological de‑differentiation and overgrowth (3).

References

  1. Schahs, P. et al. (2008) Exp. Cell Res. 314:3036.
  2. Han, Y. et al. (2008) Cardiovasc. Res. 78:597.
  3. Han, Y-L. et al. (2008) Genes Cells 13:977.
  4. Veal, E. et al. (1998) Mol. Cell. Biol. 18:5032.
  5. Veal, E. et al. (2000) Oncogene 19:2120.
  6. Xu, L. et al. (2004) J. Hypertens. 22:1579.
  7. Gordon, P.V. et al. (2005) J. Endocrinol. 185:265.
  8. Di Bacco, A. et al. (2003) Oncogene 22:5436.
  9. Journet, A. et al. (2000) Electrophoresis 21:3411.
  10. Journet, A. et al. (2002) Proteomics 2:1026.
  11. Sleat, D.E. et al. (2005) Proteomics 5:1520.
  12. Kollmann, K. et al. (2005) Proteomics 5:3966.
  13. Sleat, D.E. et al. (2006) Mol. Cell. Proteomics 5:686.
  14. Wang, N. et al. (2008) Scand. J. Immunol. 67:340.
 

Long Name

Cellular Repressor of E1A-stimulated Genes

Alternate Names

CREG1

Entrez Gene IDs

8804 (Human); 433375 (Mouse)

Gene Symbol

CREG1

UniProt

Additional CREG Products

Product Documents for Recombinant Mouse CREG Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Mouse CREG Protein

For research use only

Loading...
Loading...
Loading...